HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE-1 GP120-SPECIFIC CELL-MEDIATED CYTOTOXICITY (CMC) AND NATURAL-KILLER (NK) ACTIVITY IN HIV-INFECTED (HIV- ENHANCEMENT WITH INTERLEUKIN-2(IL-2), IL-12, AND IL-15() SUBJECTS )

Citation
Sj. Lin et al., HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE-1 GP120-SPECIFIC CELL-MEDIATED CYTOTOXICITY (CMC) AND NATURAL-KILLER (NK) ACTIVITY IN HIV-INFECTED (HIV- ENHANCEMENT WITH INTERLEUKIN-2(IL-2), IL-12, AND IL-15() SUBJECTS ), Clinical immunology and immunopathology, 82(2), 1997, pp. 163-173
Citations number
39
Categorie Soggetti
Pathology,Immunology
ISSN journal
00901229
Volume
82
Issue
2
Year of publication
1997
Pages
163 - 173
Database
ISI
SICI code
0090-1229(1997)82:2<163:H(TGC>2.0.ZU;2-L
Abstract
Cell-mediated cytotoxicity (CMC), as mediated by cytophilic antibody t o human immunodeficiency virus (HIV) antigens, may be an important def ense in HIV-infected (HIV+) patients in response to the virus. In this study the ability of interleukin (IL)-2, IL-12, and IL-15 to enhance natural killer (NK) and gp120-specific CMC of mononuclear cells (MNCs) from HIV+ children and adults was examined, NK activity against K562 cells was deficient in HIV+ patients compared to controls and could be enhanced by IL-2, IL-12, or IL-15, with the combinations of IL-2+IL-1 2 and IL-12+IL-15 producing more cytotoxicity than individual cytokine s. Gp120-specific CMC was significantly higher in patients than in con trols, It could be increased by IL-2, IL-12, and IL-15 and further by combining IL-2 and IL-12, When an exogenous source of antibody in the form of hyperimmune HIV-specific immunoglobulin (HIVIG) was present, t he response of control MNCs was much higher than that of patients, alt hough gp120-specific cytotoxicity of patients' MNCs was significantly enhanced (two-to threefold) by the addition of HMG. This increment in cytotoxicity due to HIVIG, however, could not be further augmented by cytokines in controls or patients, Our findings suggest multiple cytok ine administration to boost NK cell function, together with passive im munotherapy, might offer a new therapeutic approach to benefit HIV+ pa tients. (C) 1997 Academic Press.